Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Dogwood Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 10 | −13 |
| Shares | 1.06M | 30.6K | 30.8K | −1.00M (−97.0%) |
| Value | $180.3K | $5.20K | $76.5K | −$98.6K (−56.3%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| SBI Securities Co., Ltd. | 8 | $20 | 0.00% |
Sold out (14)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Vanguard Group Inc | 208,883 | $35.5K |
| HRT Financial LP | 81,574 | $13.0K |
| Two Sigma Securities, LLC | 53,392 | $9.08K |
| State Street Corp | 52,828 | $8.98K |
| McCollum Christoferson Group LLC | 33,500 | $5.70K |
| Jane Street Group, LLC | 28,032 | $4.76K |
| Northern Trust Corp | 24,035 | $4.09K |
| Regions Financial Corp | 20,072 | $3.41K |
| One + One Wealth Management, LLC | 20,000 | $3.40K |
| Renaissance Technologies LLC | 16,500 | $2.81K |
| William Howard & Co Financial Advisors Inc | 10,072 | $2.00K |
| Wiley Bros.-Aintree Capital, LLC | 11,000 | $1.87K |
| Cetera Investment Advisers | 10,582 | $1.80K |
| Simplex Trading, LLC | 100 | $0 |
Not filed for Q4 2024 yet (1)
Institutions that held Dogwood Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 30,600 | $5.20K |